

## 14\_Miscellaneous: PAH, Structural Heart, Cardiomyopathy, Clinical Trials

May 18, 2018 (Friday)

10:30-12:00

1

### Overview of Pulmonary Hypertension

Chair 1: TBA

Chair 2: TBA

- |    |                |  |
|----|----------------|--|
| 20 | <b>Topic 1</b> | Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension<br><b>Steven H. Abman (USA)</b> |
| 20 | <b>Topic 2</b> | Therapeutic Options for Childhood Pulmonary Hypertension Associated with Congenital Heart Disease<br><b>TBA</b>                      |
| 20 | <b>Topic 3</b> | Updates in the Management of Left Heart Disease Related Pulmonary Hypertension<br><b>Takeshi Ogo (Japan)</b>                         |
| 20 | <b>Topic 4</b> | Pulmonary Hypertension in Taiwan<br><b>TBA</b>   |

13:30-15:00

2

### Recent Update in CTEPH Management

Chair 1: TBA

Chair 2: TBA

- |    |                |   |
|----|----------------|---|
| 20 | <b>Topic 1</b> | Recent Update in CTEPH Diagnosis and Medical Therapy<br><b>Nick Kim (USA)</b> |
| 20 | <b>Topic 2</b> | Surgical Management for CTEPH<br><b>TBA</b>                                   |
| 20 | <b>Topic 3</b> | Balloon Pulmonary Angioplasty for CTEPH<br><b>Takeshi Ogo (Japan)</b>         |
| 20 | <b>Topic 4</b> | Challenging Cases in CTEPH<br><b>TBA</b>                                      |

15:30-17:00

3

### Pulmonary Hypertension in Connective Tissue Disease

Chair 1: TBA

Chair 2: TBA

- |    |                |   |
|----|----------------|---|
| 20 | <b>Topic 1</b> | The Unsolved Problems in CTD Associated Pulmonary Hypertension<br><b>Nick Kim (USA)</b> |
| 20 | <b>Topic 2</b> | Advanced Molecular Pathophysiology of Pulmonary Hypertension<br><b>TBA</b>              |
| 20 | <b>Topic 3</b> | Treatment Strategy for CTD-PAH in Taiwan<br><b>TBA</b>                                  |
| 20 | <b>Topic 4</b> | Lung Transplant of PAH in Japan<br><b>TBA</b>   |

## May 19, 2018 (Saturday)

08:30-10:00

4

### Percutaneous Intervention of Valvular Heart Diseases

**Chair 1:** TBA

**Chair 2:** TBA

- |    |                |   |
|----|----------------|---|
| 20 | <b>Topic 1</b> | Too Little, Too Late: When Does TAVI Become Futile?<br><b>TBA</b> |
| 20 | <b>Topic 2</b> | Mitral Valve Clips and Update<br><b>TBA</b>                       |
| 20 | <b>Topic 3</b> | Percutaneous Intervention of Tricuspid Valve<br><b>TBA</b>        |
| 20 | <b>Topic 4</b> | Percutaneous Intervention of Pulmonary Valve<br><b>TBA</b>        |

10:30-12:00

5

### Cardiomyopathy and Update

**Chair 1:** TBA

**Chair 2:** TBA

- |    |                |   |
|----|----------------|---|
| 20 | <b>Topic 1</b> | Fabry Disease, Focus on the Cardiac Variant in Taiwan<br><b>TBA</b>   |
| 20 | <b>Topic 2</b> | HOCM<br><b>TBA</b>  |
| 20 | <b>Topic 3</b> | Role of Cardiac MRI in the Management of Cardiomyopathy<br><b>TBA</b> |
| 20 | <b>Topic 4</b> | Next Generation Sequencing in Cardiomyopathy<br><b>TBA</b>            |

13:30-15:00

6

### Meet with Pivotal Clinical Trialists 1

**Chair 1:** TBA

**Chair 2:** TBA

- |      |                |   |
|------|----------------|---|
| Time | <b>Topic 1</b> | FOURIER Trial: Clinical Implication<br><b>TBA</b> |
| Time | <b>Topic 2</b> | CANVAS Trial: Clinical Implication<br><b>TBA</b>  |
| Time | <b>Topic 3</b> | ODYSSEY Trial: Clinical Implication<br><b>TBA</b> |
| Time | <b>Topic 4</b> | CANTOS Trial: Clinical Implication<br><b>TBA</b>  |

15:30-17:00

7

**Meet with Pivotal Clinical Trialists 2**

**Chair 1:** TBA

**Chair 2:** TBA

Time **Topic 1** REVEAL Trial: Clinical Implication  
**TBA**

Time **Topic 2** LINQ REVEAL Trial: Clinical Implication  
**TBA**

Time **Topic 3** Topic 3  
**TBA**

Time **Topic 4** Topic 4  
**TBA**

**May 20, 2018 (Sunday)**

08:30-10:00

8

**Oral Session**

**Chair 1:** TBA

**Chair 2:** TBA

15 **Speaker 1** Topic 1  
**TBA**

15 **Speaker 2** Topic 2  
**TBA**

15 **Speaker 3** Topic 3  
**TBA**

15 **Speaker 4** Topic 4  
**TBA**

15 **Speaker 5** Topic 3  
**TBA**

15 **Speaker 6** Topic 4  
**TBA**